CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
Abstract Calcitonin gene-related peptide (CGRP) is a neuropeptide with a pivotal role in the pathophysiology of migraine. Blockade of CGRP is a new therapeutic target for patients with migraine. CGRP and its receptors are distributed not only in the central and peripheral nervous system but also in...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-03-01
|
Series: | The Journal of Headache and Pain |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s10194-019-0979-y |
id |
doaj-3f520af052184d799239d103d0cba89f |
---|---|
record_format |
Article |
spelling |
doaj-3f520af052184d799239d103d0cba89f2020-11-25T02:25:11ZengBMCThe Journal of Headache and Pain1129-23691129-23772019-03-012011710.1186/s10194-019-0979-yCGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?Valentina Favoni0Luca Giani1Linda Al-Hassany2Gian Maria Asioli3Calogera Butera4Irene de Boer5Martina Guglielmetti6Chrysoula Koniari7Theodoros Mavridis8Marge Vaikjärv9Iris Verhagen10Angela Verzina11Bart Zick12Paolo Martelletti13Simona Sacco14European Headache Federation School of Advanced Studies (EHF-SAS)Department of Biomedical and Neuromotor Sciences, University of BolognaRicovero Ferdinando UboldiDivision of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MCDepartment of Biomedical and Neuromotor Sciences, University of BolognaDipartimento Neurologico e INSPE, IRCCS Ospedale San RaffaeleDepartment of Neurology, Leiden University Medical CenterDepartment of Clinical and Molecular Medicine, Sapienza University1st Neurology Department, Aeginition Hospital, School of Medicine, National and Kapodistrian University of Athens1st Neurology Department, Aeginition Hospital, School of Medicine, National and Kapodistrian University of AthensFaculty of Medicine, University of TartuDivision of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MCNeurology Clinic, University of PerugiaDivision of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MCDepartment of Clinical and Molecular Medicine, Sapienza UniversityUOC Neurologia e Stroke Unit, Ospedale SS Filippo e NicolaAbstract Calcitonin gene-related peptide (CGRP) is a neuropeptide with a pivotal role in the pathophysiology of migraine. Blockade of CGRP is a new therapeutic target for patients with migraine. CGRP and its receptors are distributed not only in the central and peripheral nervous system but also in the cardiovascular system, both in blood vessels and in the heart. We reviewed the current evidence on the role of CGRP in the cardiovascular system in order to understand the possible short- and long-term effect of CGRP blockade with monoclonal antibodies in migraineurs. In physiological conditions, CGRP has important vasodilating effects and is thought to protect organs from ischemia. Despite the aforementioned cardiovascular implication, preventive treatment with CGRP antibodies has shown no relevant cardiovascular side effects. Results from long-term trials and from real life are now needed.http://link.springer.com/article/10.1186/s10194-019-0979-yCGRPCGRP antibodyMigraine treatmentCardiovascular |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Valentina Favoni Luca Giani Linda Al-Hassany Gian Maria Asioli Calogera Butera Irene de Boer Martina Guglielmetti Chrysoula Koniari Theodoros Mavridis Marge Vaikjärv Iris Verhagen Angela Verzina Bart Zick Paolo Martelletti Simona Sacco European Headache Federation School of Advanced Studies (EHF-SAS) |
spellingShingle |
Valentina Favoni Luca Giani Linda Al-Hassany Gian Maria Asioli Calogera Butera Irene de Boer Martina Guglielmetti Chrysoula Koniari Theodoros Mavridis Marge Vaikjärv Iris Verhagen Angela Verzina Bart Zick Paolo Martelletti Simona Sacco European Headache Federation School of Advanced Studies (EHF-SAS) CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? The Journal of Headache and Pain CGRP CGRP antibody Migraine treatment Cardiovascular |
author_facet |
Valentina Favoni Luca Giani Linda Al-Hassany Gian Maria Asioli Calogera Butera Irene de Boer Martina Guglielmetti Chrysoula Koniari Theodoros Mavridis Marge Vaikjärv Iris Verhagen Angela Verzina Bart Zick Paolo Martelletti Simona Sacco European Headache Federation School of Advanced Studies (EHF-SAS) |
author_sort |
Valentina Favoni |
title |
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? |
title_short |
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? |
title_full |
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? |
title_fullStr |
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? |
title_full_unstemmed |
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? |
title_sort |
cgrp and migraine from a cardiovascular point of view: what do we expect from blocking cgrp? |
publisher |
BMC |
series |
The Journal of Headache and Pain |
issn |
1129-2369 1129-2377 |
publishDate |
2019-03-01 |
description |
Abstract Calcitonin gene-related peptide (CGRP) is a neuropeptide with a pivotal role in the pathophysiology of migraine. Blockade of CGRP is a new therapeutic target for patients with migraine. CGRP and its receptors are distributed not only in the central and peripheral nervous system but also in the cardiovascular system, both in blood vessels and in the heart. We reviewed the current evidence on the role of CGRP in the cardiovascular system in order to understand the possible short- and long-term effect of CGRP blockade with monoclonal antibodies in migraineurs. In physiological conditions, CGRP has important vasodilating effects and is thought to protect organs from ischemia. Despite the aforementioned cardiovascular implication, preventive treatment with CGRP antibodies has shown no relevant cardiovascular side effects. Results from long-term trials and from real life are now needed. |
topic |
CGRP CGRP antibody Migraine treatment Cardiovascular |
url |
http://link.springer.com/article/10.1186/s10194-019-0979-y |
work_keys_str_mv |
AT valentinafavoni cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT lucagiani cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT lindaalhassany cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT gianmariaasioli cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT calogerabutera cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT irenedeboer cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT martinaguglielmetti cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT chrysoulakoniari cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT theodorosmavridis cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT margevaikjarv cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT irisverhagen cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT angelaverzina cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT bartzick cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT paolomartelletti cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT simonasacco cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp AT europeanheadachefederationschoolofadvancedstudiesehfsas cgrpandmigrainefromacardiovascularpointofviewwhatdoweexpectfromblockingcgrp |
_version_ |
1724852501652439040 |